Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ARCA BIOPHARMA INC (ABIO) Stock Price & Overview
NASDAQ:ABIO • US00211Y5069
Current stock price
2.4 USD
-0.1 (-4%)
At close:
2.48 USD
+0.08 (+3.33%)
After Hours:
The current stock price of ABIO is 2.4 USD. Today ABIO is down by -4%. In the past month the price decreased by -22.83%. In the past year, price increased by 16.57%.
ABIO Key Statistics
52-Week Range1.56 - 4.49
Current ABIO stock price positioned within its 52-week range.
1-Month Range1.81 - 4.36
Current ABIO stock price positioned within its 1-month range.
- Market Cap
- 34.824M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.50
- Dividend Yield
- 67.21%
ABIO Stock Performance
Today
-4%
1 Week
-42.31%
1 Month
-22.83%
3 Months
-35.14%
Longer-term
6 Months +43.71%
1 Year +16.57%
2 Years +2.56%
3 Years -22.33%
5 Years -57.30%
10 Years -98.64%
ABIO Stock Chart
ABIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ABIO. When comparing the yearly performance of all stocks, ABIO is a bad performer in the overall market: 75.71% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ABIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABIO. ABIO has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ABIO Earnings
Next Earnings DateOct 16, 2024
Last Earnings DateJul 31, 2024
PeriodQ2 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ABIO Forecast & Estimates
Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
ABIO Financial Highlights
Over the last trailing twelve months ABIO reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -13.18% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-7.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.27% | ||
| ROE | -22.1% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-79.73%
Sales Q2Q%N/A
EPS 1Y (TTM)-13.18%
Revenue 1Y (TTM)N/A
ABIO Ownership
Ownership
Inst Owners0.05%
Shares14.51M
Float14.37M
Ins Owners61.11%
Short Float %N/A
Short RatioN/A
ABIO Industry Overview
ABIO operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
ABIO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABIO
Company Profile
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
Company Info
IPO: 2000-07-21
ARCA BIOPHARMA INC
10170 Church Ranch Way, Suite 100
Westminster COLORADO 80021 US
CEO: Michael R. Bristow
Employees: 4
Phone: 17209402200
ARCA BIOPHARMA INC / ABIO FAQ
What does ABIO do?
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
Can you provide the latest stock price for ARCA BIOPHARMA INC?
The current stock price of ABIO is 2.4 USD. The price decreased by -4% in the last trading session.
Does ABIO stock pay dividends?
ARCA BIOPHARMA INC (ABIO) has a dividend yield of 67.21%. The yearly dividend amount is currently 0.
What is the ChartMill rating of ARCA BIOPHARMA INC stock?
ABIO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does ARCA BIOPHARMA INC have?
ARCA BIOPHARMA INC (ABIO) currently has 4 employees.